C David Pauza

List of Publications by Year
in descending order

30	1,215	394421	477307
papers	citations	19 h-index	29 g-index

30	30	30	1613
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection. Journal of Immunology, 2021, 207, 1310-1321.	0.8	5
2	Human cytomegalovirus evades antibody-mediated immunity through endoplasmic reticulum-associated degradation of the FcRn receptor. Nature Communications, 2019, 10, 3020.	12.8	21
3	Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Frontiers in Immunology, 2018, 9, 1305.	4.8	80
4	An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. Vaccine Journal, 2017, 24, .	3.1	8
5	Interleukinâ€18 activates VÎ³9VÎ´2‹sup›+‹/sup› T cells from HIVâ€positive individuals: recovering the response to phosphoantigen. Immunology, 2017, 151, 385-394.	4.4	12
6	Cancer Diagnostic and Predictive Biomarkers 2016. BioMed Research International, 2017, 2017, 1-2.	1.9	9
7	Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population. SAGE Open Medicine, 2017, 5, 205031211772564.	1.8	1
8	Prolonged PD1 Expression on Neonatal VÎ´2 Lymphocytes Dampens Proinflammatory Responses: Role of Epigenetic Regulation. Journal of Immunology, 2016, 197, 1884-1892.	0.8	23
9	Cancer Diagnostic and Predictive Biomarkers 2015. BioMed Research International, 2015, 2015, 1-1.	1.9	0
10	Evolution and function of the TCR Vgamma9 chain repertoire: Itâ€™s good to be public. Cellular Immunology, 2015, 296, 22-30.	3.0	35
11	V‹i›Î³‹/i›2V‹i›Î´‹/i›2 Tâ€cell coâ€stimulation increases natural killer cell killing of monocyteâ€derived dendritic cells. Immunology, 2015, 144, 422-430.	4.4	17
12	Levels of CD56+TIM-3- Effector CD8 T Cells Distinguish HIV Natural Virus Suppressors from Patients Receiving Antiretroviral Therapy. PLoS ONE, 2014, 9, e88884.	2.5	20
13	ÃŽÂ³ÃŽÂ´ T Cells in HIV Disease: Past, Present, and Future. Frontiers in Immunology, 2014, 5, 687.	4.8	66
14	Human cord blood Î³Î´ ‹scp›T‹/scp› cells expressing public VÎ³2 chains dominate the response to bisphosphonate plus interleukinâ€15. Immunology, 2013, 138, 346-360.	4.4	22
15	The Î³Î´ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy. Aids, 2013, 27, 1557-1562.	2.2	26
16	Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy, 2012, 14, 173-181.	0.7	36
17	Targeting Î³Î´ T cells for immunotherapy of HIV disease. Future Virology, 2011, 6, 73-84.	1.8	16
18	HIV envelope-mediated, CCR5/Î±4Î²7-dependent killing of CD4-negative Î³Î´ T cells which are lost during progression to AIDS. Blood, 2011, 118, 5824-5831.	1.4	48

#	Article	IF	Citations
19	A Neonatal Fc Receptor-Targeted Mucosal Vaccine Strategy Effectively Induces HIV-1 Antigen-Specific Immunity to Genital Infection. Journal of Virology, 2011, 85, 10542-10553.	3.4	96
20	Human Î³Î´ T lymphocytes induce robust NK cellâ€“mediated antitumor cytotoxicity through CD137 engagement. Blood, 2010, 116, 1726-1733.	1.4	170
21	Control of CD56 expression and tumor cell cytotoxicity in human VÎ³2VÎ´2 T cells. BMC Immunology, 2009, 10, 50.	2.2	26
22	Natural viral suppressors of HIV-1 have a unique capacity to maintain Î³Î´ T cells. Aids, 2009, 23, 1955-1964.	2.2	43
23	Failure to restore the VÎ³2-JÎ³1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clinical Immunology, 2008, 128, 349-357.	3.2	25
24	Association between VÎ³2VÎ´2 T Cells and Disease Progression after Infection with Closely Related Strains of HIV in China. Clinical Infectious Diseases, 2008, 46, 1466-1472.	5.8	41
25	Isopentenyl Pyrophosphateâ€“Activated CD56+ Î³Î´ T Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 4232-4240.	7.0	143
26	The Vgamma2/Vdelta2 T-cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vgamma2/Jgamma1.2 subset. Immunology, 2005, 115, 197-205.	4.4	13
27	Association between Longer Duration of HIVâ€Suppressive Therapy and Partial Recovery of the VÎ³2 T Cell Receptor Repertoire. Journal of Infectious Diseases, 2004, 189, 1482-1486.	4.0	43
28	HIV-MediatedÎ³Î´T Cell Depletion Is Specific for VÎ³2+Cells Expressing the JÎ³1.2 Segment. AIDS Research and Human Retroviruses, 2003, 19, 21-29.	1.1	38
29	In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology, 2001, 104, 19-27.	4.4	58
30	Functional Î³Î´ T-lymphocyte Defect Associated with Human Immunodeficiency Virus Infections. Molecular Medicine, 1997, 3, 60-71.	4.4	74